Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Adaptive, Phase 2, Randomized, Open-label Study of Irradiated Autologous Cellular Vaccine in Men With High-Risk Prostate Cancer Following Prostatectomy

NCT06636682 is registered in ClinicalTrials.gov with Cellvax Therapeutics Inc as lead sponsor.

NCT NCT06636682
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06636682 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Adaptive, Phase 2, Randomized, Open-label Study of Irradiated Autologous Cellular Vaccine in Men With High-Risk Prostate Cancer Following Prostatectomy
Lead sponsor
Cellvax Therapeutics Inc
Phase
Phase 2
Overall status
Recruiting
Start date
October 14, 2024
Completion date
May 4, 2027
Enrollment
100 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

high-risk prostate cancer, prostate ca, prostate cancer, prostate cancer (adenocarcinoma), prostate cancer (post prostatectomy), prostate cancer patients undergoing radical prostatectomy, prostate cancers